Vaginal Microbial Profile of Cervical Cancer Patients Receiving Chemoradiotherapy: the Potential Involvement of Lactobacillus Iners in Recurrence

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2024 Jun 17

PMID 38886729

Authors

Yichen Wang

Tingzhang Wang

Dingding Yan

Hongxia Zhao

Meixia Wang

Tingting Liu

Xiaoji Fan

Xiaoxian Xu

Affiliations

Soon will be listed here.

Abstract

The vaginal microbiome is an immune defense against reproductive diseases and can serve as an important biomarker for cervical cancer. However, the intrinsic relationship between the recurrence and the vaginal microbiome in patients with cervical cancer before and after concurrent chemoradiotherapy is poorly understood. Here, we analyzed 125 vaginal microbial profiles from a patient cohort of stage IB-IVB cervical cancer using 16S metagenomic sequencing and deciphered the microbial composition and functional characteristics of the recurrent and non-recurrent both before and after chemoradiotherapy. We demonstrated that the abundance of beneficial bacteria and stability of the microbial community in the vagina decreased in the recurrence group, implying the unique characteristics of the vaginal microbiome for recurrent cervical cancer. Moreover, using machine learning, we identified Lactobacillus iners as the most important biomarker, combined with age and other biomarkers (such as Ndongobacter massiliensis, Corynebacterium pyruviciproducens ATCC BAA-1742, and Prevotella buccalis), and could predict cancer recurrence phenotype before chemoradiotherapy. This study prospectively employed rigorous bioinformatics analysis and highlights the critical role of vaginal microbiota in post-treatment cervical cancer recurrence, identifying promising biomarkers with prognostic significance in the context of concurrent chemoradiotherapy for cervical cancer. The role of L. iners in determining chemoradiation resistance in cervical cancer warrants further detailed investigation. Our results expand our understanding of cervical cancer recurrence and help develop better strategies for prognosis prediction and personalized therapy.

References

Cong J, Zhang Y, Xue Y, Zhang C, Xu M, Liu D . A Pilot Study: Changes of Intestinal Microbiota of Patients With Non-small Cell Lung Cancer in Response to Osimertinib Therapy. Front Microbiol. 2020; 11:583525. PMC: 7683577. DOI: 10.3389/fmicb.2020.583525. View

Ferris M, Norori J, Zozaya-Hinchliffe M, Martin D . Cultivation-independent analysis of changes in bacterial vaginosis flora following metronidazole treatment. J Clin Microbiol. 2007; 45(3):1016-8. PMC: 1829144. DOI: 10.1128/JCM.02085-06. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Ivanov M, Brenner E, Hodkevich A, Dzyubenko V, Krasilnikov S, Mansurova A . Cervicovaginal-Microbiome Analysis by 16S Sequencing and Real-Time PCR in Patients from Novosibirsk (Russia) with Cervical Lesions and Several Years after Cancer Treatment. Diagnostics (Basel). 2023; 13(1). PMC: 9818139. DOI: 10.3390/diagnostics13010140. View

Ravel J, Gajer P, Abdo Z, Schneider G, Koenig S, McCulle S . Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A. 2010; 108 Suppl 1:4680-7. PMC: 3063603. DOI: 10.1073/pnas.1002611107. View

Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z . Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. J Clin Oncol. 2018; 36(27):2796-2803. PMC: 6145832. DOI: 10.1200/JCO.2018.79.1483. View

Laniewski P, Ilhan Z, Herbst-Kralovetz M . The microbiome and gynaecological cancer development, prevention and therapy. Nat Rev Urol. 2020; 17(4):232-250. PMC: 9977514. DOI: 10.1038/s41585-020-0286-z. View

Ruiz F, Pascual L, Giordano W, Barberis L . Bacteriocins and other bioactive substances of probiotic lactobacilli as biological weapons against Neisseria gonorrhoeae. Pathog Dis. 2015; 73(3). DOI: 10.1093/femspd/ftv013. View

Bloom S, Mafunda N, Woolston B, Hayward M, Frempong J, Abai A . Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol. 2022; 7(3):434-450. PMC: 10473153. DOI: 10.1038/s41564-022-01070-7. View

10.

Champer M, Wong A, Champer J, Brito I, Messer P, Hou J . The role of the vaginal microbiome in gynaecological cancer. BJOG. 2017; 125(3):309-315. DOI: 10.1111/1471-0528.14631. View

11.

Faubert B, Li K, Cai L, Hensley C, Kim J, Zacharias L . Lactate Metabolism in Human Lung Tumors. Cell. 2017; 171(2):358-371.e9. PMC: 5684706. DOI: 10.1016/j.cell.2017.09.019. View

12.

Lee A, Ng W, Chan L, Hung W, Chan C, Sze H . Evolution of treatment for nasopharyngeal cancer--success and setback in the intensity-modulated radiotherapy era. Radiother Oncol. 2014; 110(3):377-84. DOI: 10.1016/j.radonc.2014.02.003. View

13.

Ponziani F, De Luca A, Picca A, Marzetti E, Petito V, Del Chierico F . Gut Dysbiosis and Fecal Calprotectin Predict Response to Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma. Hepatol Commun. 2022; 6(6):1492-1501. PMC: 9134810. DOI: 10.1002/hep4.1905. View

14.

Gajer P, Brotman R, Bai G, Sakamoto J, Schutte U, Zhong X . Temporal dynamics of the human vaginal microbiota. Sci Transl Med. 2012; 4(132):132ra52. PMC: 3722878. DOI: 10.1126/scitranslmed.3003605. View

15.

Wang J, Wang T, Yang Y, Chai Y, Shi F, Liu Z . Patient age, tumor appearance and tumor size are risk factors for early recurrence of cervical cancer. Mol Clin Oncol. 2015; 3(2):363-366. PMC: 4360871. DOI: 10.3892/mco.2014.465. View

16.

Qin H, Jiao J, A D, Hua M, Han K, Du H . Single-Molecule Approach to 16S rRNA for Vaginal Microbiome Signatures in Response to Metronidazole Treatment. Microbiol Spectr. 2023; 11(3):e0170622. PMC: 10269914. DOI: 10.1128/spectrum.01706-22. View

17.

France M, Alizadeh M, Brown S, Ma B, Ravel J . Towards a deeper understanding of the vaginal microbiota. Nat Microbiol. 2022; 7(3):367-378. PMC: 8910585. DOI: 10.1038/s41564-022-01083-2. View

18.

Li H, Wu X, Cheng X . Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol. 2016; 27(4):e43. PMC: 4864519. DOI: 10.3802/jgo.2016.27.e43. View

19.

Mendes-Soares H, Suzuki H, Hickey R, Forney L . Comparative functional genomics of Lactobacillus spp. reveals possible mechanisms for specialization of vaginal lactobacilli to their environment. J Bacteriol. 2014; 196(7):1458-70. PMC: 3993339. DOI: 10.1128/JB.01439-13. View

20.

Zhang Q, Guo J, Ouyang H, Chen S, Zhao X, Yu X . Added-value of dynamic contrast-enhanced MRI on prediction of tumor recurrence in locally advanced cervical cancer treated with chemoradiotherapy. Eur Radiol. 2021; 32(4):2529-2539. DOI: 10.1007/s00330-021-08279-w. View